Recurring, site-specific chromosomal rearrangements are associated with several human syndromes and malignant disorders. Such nonrandom translocations involving chromosome 22 in band qil are numerous and found to be associated with a diversity ofneoplasms as well as constitutional disorders. Chromosome 11 in bands q23-q24 is similarly involved in several types of tumors as well as in a recurring constitutional reciprocal translocation with chromosome 22. Here we report the use of chromosomal in situ hybridization to compare the translocation breakpoints in the cytologically indistinguishable constitutional t(l1122) and the tumor-related t(l;22) associated with Ewing sarcoma and peripheral neuroepithelioma. We have shown that the breakpoints can be distinguished from each other with iespect to the locus encoding the constant region of the Ig A light chain (Co) at 22q11 and the ETSI locus at 1lq23--q24; ETSI has been called hu-ets-l or human cgets-l. The tumor-associated chromosome 11 breakpoint is also different from those of leukemias with t(9;11) and t(4;11) translocations, Southern-blot analysis showed no rearrangement ofETSI in these disorders in the region detected by our probe. ETSI has also been mapped more precisely to 11q23.3-+q24 by in situ hybridization to cells from an individual with an 11q23.3--qter deletion.
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Site-specific chromosome rearrangements are associated with both malignant and nonmalignant human disorders. Recurrent rearrangements involving chromosome 22 have been described both in the constitutional karyotype and as acquired somatic abnormalities in neoplastic diseases (1, 2) . The breakpoints of the t(9;22) of chronic myelogenous leukemia, the t(9;22) of acute lymphocytic leukemia, and the t(8;22) of Burkitt lymphoma within 22q11 are cytologically indistinguishable. Chromosomal in situ hybridization has been used to map these translocation breakpoints more precisely and has shown that, in fact, the 22q11 breakpoints can be distinguished from each other at a molecular level (3, 4) .
Recently, chromosome 22 has been shown to be involved in a reciprocal translocation with chromosome 11, t(11;22)-(q23-q24;qll-q12) in virtually all cases of swing sarcoma (ES) and peripheral neuroepithelioma (NE) examined cytogenetically (5) (6) (7) (8) (9) (10) . Askin tumor, a malignancy of the thoracopulmonary region, also has been found recently to have an apparently identical t(11;22) (10) and is likely a neuroepithelioma of the chest wall (11, 12) . Recurrent rearrangements involving chromosome 11 at q23-q24 have also been reported in leukemias, including the t(4;11)(q21;q23) of acute lymphoblastic or undifferentiated leukemia (13) and the t(9;11)(q21;q23) of acute monocytic leukemia (14) .
The 11;22 rearrangement of ES, NE, and Askin tumor is cytologically indistinguishable from the recurrent constitutional chromosomal rearrangement that has been described (1) , which involves the same chromosomal regions. The constitutional t(11;22)(q23;q11) is a site-specific, reciprocal translocation that has now been described in more than 110 unrelated families (1, 15) . Balanced carriers are phenotypically normal and at no apparent increased risk for neoplasia. The translocation is usually detected after the birth of phenotypically abnormal progeny who carry the derivative chromosome 22 as a supernumerary chromosome. This 11;22 translocation is one ofthe most common reciprocal translocations in the constitutional karyotype of man. While the breakpoints of the rearrangement given by different authors vary between bands q23 and q25 of chromosome 11 and bands qil and q13 of chromosome 22 (15, 16) , they are, in practice, cytologically indistinguishable from each other. Molecular data suggest that the breakpoint is in 22q11 (17) ; therefore, the complementary breakpoint in chromosome 11 would have to be q23 to give the observed derivative chromosomes.
We have used chromosomal in situ hybridization to compare this constitutional 11;22 translocation with the 11;22 translocation associated with ES and NE. Using a portion of the constant (C) region of the immunoglobulin X light chain gene (C) and the protooncogene ETS1 (human homolog of the E26 acute avian oncogene ets-1, often referred to as hu-ets-1) as probes, we have shown that the breakpoints within 22q11 and 11q23 appear to be alike in four constitutional translocation carriers but clearly distinguishable from the cytologically similar breakpoints associated with ES and NE. The ETSJ locus also has been sublocalized more precisely to the region 11q23.3--q24 by using cells carrying an llq23.3--qter deletion. (10) .
MATERIALS AND METHODS
Probes. pCX is an 8.0-kilobase (kb) EcoRI genomic fragment of-the C region of the human immunoglobulin X light chain in pBR322 (19) . It contains the coding regions for CX2 and CA3 and has been shown to map to 22q11 (19, 20) . The DNA probe for the human protooncogene ETS1 is a 5.4-kb EcoRI fragment of genomic DNA in plasmid pKH47 (21) , which has been shown to map to 11q23-+q24, and which represents a portion of the ETS1 locus.
In Situ Hybridization. 3H-labeling of DNA and in situ hybridization were performed by using a protocol modified from several in the literature that has been described in detail (22) . Concentrations of probe DNA used were 0.035-0.11 ,ig/ml. Slides were exposed to Kodak NTB-2 liquid track emulsion for 3-21 days, developed, and stained for Gbanding by using a modified Wright Giemsa protocol (23). Seventy-five to 100 metaphase spreads were analyzed from each individual or cell line for each probe. Locations ofgrains on chromosomes were recorded. Because of the limited technical quality of banding of the preparations from the tumor cells, chromosomes 22, 22q-, 11, and iiq+ were identified individually whenever possible and by group (G and C, respectively) when necessary.
Southern-Blot Analysis. DNA was isolated from tumorderived cell lines and from normal tissues of the same individual when available by using the procedure of Britten et al. (24) . Genomic DNA (20 ,ug) (25) . The ETS1 probe was labeled with 32P-labeled deoxynucleotides by using a nick-translation kit (Amersham). Hybridization and washing procedures have been described elsewhere (26) .
RESULTS
Partial karyotypes showing chromosomes 11 and 22 from two constitutional t (11;22) carriers, one ES cell line, and one NE cell line, are shown in Fig. 1 to illustrate the similarity of the constitutional and tumor-related breakpoints on chromosomes 11 and 22. The terminal deletion in individual SH, del(ll)(q23.3-)qter) (Fig. 2) is in the same region of iiq as are the constitutional and tumor-related translocations of chromosome 11. The results of in situ hybridization of labeled pCX DNA to metaphase chromosome preparations from two constitutional t (11;22) carriers are summarized in Table. I. Preliminary results from 26 previously reported metaphases (17) are included in the results for GM6229. In the two constitutional t(11;22) carriers GM6229 and HD, pCX hybridized to its normal site on chromosome 22 and also to the iiq+ chromosome, with no significant hybridization to the 22q-(derivative chromosome 22) . In contrast to the results for the constitutional t(11;22) and similar to previously reported results for the tumor-related rearrangement (17) , the pCX probe hybridized to both the normal and derivative chromosomes 22 in the ES cell line ML, with an additional large percentage ofgrains on G-group chromosomes, which, due to limited technical quality, could not be identified absolutely in some metaphases. Thus, taken together with previous results, the breakpoint on chromosome 22 is proximal to the CA locus in the five constitutional translocation carriers examined and distal to the C), locus in the four tumors examined.
In situ hybridization of labeled ETSJ DNA (Table 2) to metaphase chromosome spreads from the four constitutional t(11;22) carriers showed significant hybridization to the normal site at llq23-*q24 and also to the 22q-chromosome. Thus, ETSJ translocates to the derivative chromosome 22 in the constitutional t(11;22) translocation. In contrast, there was no significant hybridization tp the derivative chromosome 22 (Table 3 and Fig. 3 ) in either of the two ES cell lines or the two NE cell lines that we'examined. Thus, the breakpoint on chromosome 11 is proximal to the ETSJ locus in the four constitutional translocation carriers examined and distal to ETSJ in the four tumor-associated 11;22 rearrangements examined.
Ninety-eight metaphases from SH were hybridized with labeled ETSJ DNA to localize more precisely the ETS1 locus 4 Upper is a representative autoradiograph showing results of a Southern-blot analysis of 6 of these lines. DNA isolated from 3 NE cell lines, normal tissue from the same 3 individuals, and 3 ES cell lines was cleaved with Apa I and probed with 32P-labeled ETS). Apa I cleaves twice within the region recognized by the probe to produce a 2.3-kb fragment. The 5' flanking genomic fragment is 9 kb, and the 3' flanking genomic fragment is 10 kb, as shown in Fig. 4 (2), in which the ABL (human c-abl) oncogene from chromosome 9 is brought adjacent to the breakpoint cluster region on chromosome 22 (27) . This results in a chimeric mRNA that produces a fusion protein with acquired protein-tyrosine kinase activity (28) (29) (30) (31) (32) . The derivative chromosome 22 also occurs in acute lymphocytic leukemia, but the genetic mechanism of ABL activation or involvement is less clear (34 Translocation breakpoint mapping of the constitutional t (11;22) and the cytogenetically similar translocation of ES, NE, and Askin tumor has allowed us to determine molecular differences between these cytologically indistinguishable translocations. Data has been presented that showed that the breakpoint within 22q11 is proximal to CA in three constitutional t(11;22) carriers and distal to CA in one ES cell line and two NE cell lines with the t(11;22) translocation (17) . We have confirmed and extended these results with one additional constitutional translocation carrier and one additional ES cell line. In a similar fashion, we now can distinguish the breakpoint on chromosome 11 with reference to the ETSI gene. We have shown that the breakpoint is proximal to ETS1 (6) 2 (1) 1 (<1) *Percentages of total grains are shown in parentheses.
in four constitutional t (11;22) carriers and distal to ETS1 in the four tumors examined (Fig. 5) . The ETSJ locus appears to be located within or distal to 11q23.3 on the basis of our in situ hybridization to cells from an individual with a de novo deletion in llq, since we did not find significant hybridization to the llq-chromosome. It is, however, possible that the ETSJ gene was interrupted by the translocation and the sequences remaining on the llq-chromosome are outside the region recognized by our current probe. Unfortunately, neither DNA nor metaphase spreads from this now deceased individual are available to look for rearrangement ofthe ETSJ locus.
The cell of origin for ES is unknown; NE is of neuroectodermal origin (11) . Recent work by Whang-Peng et al. (10) has described a cytologically indistinguishable t(11;22) in 22 cases of ES, 5 cases ofNE, and 5 Askin tumors. An additional neuroepithelioma with t(11;22) is described by de Chadarevian et al. (6) . To date, no site-specific, recurrent chromosomal translocation has yet been described in tumors arising from histologically distinct tissues. Our finding that the breakpoints on chromosomes 11 and 22 for two NE and two ES cell lines are indistinguishable from each other with respect to the location of ETSJ and CA genes lends further support to the similarity of these tumors and credence to the possibility that neuroepithelioma and ES arise from a common precursor cell (10) . The chromosome 11 breakpoint of ES and NE cell lines is distal to ETSJ and, thus, is clearly different from that of two cases of monocytic leukemia with t(9;11)(p22;q23) (14) and of one case of t(4;11) leukemia (13) reported, in which the breakpoints are proximal to ETSJ.
The role of oncogenes in 11;22 translocations, both constitutional and tumor-related, remains unclear. SIS (human c-sis), which has been mapped to 22q13 (34) and is therefore far distal to the region of chromosome 22 involved in these translocations, is translocated in ES (35, 36) and NE (37) cell lines, and there is no evidence of activation or rearrangement of SIS (35) (36) (37) 11 showing the relative locations of the breakpoints for four constitutional t (11;22) carriers and four tumor-related t (11;22) translocations with respect to the ETSJ locus (hu-ets-1). As indicated, ETSJ is located either in the distal portion of 11q23 or in the proximal portion of 11q24 and is proximal to the tumor-associated breakpoint. moving a protooncogene from its normal chromosomal location in the genome is not sufficient in itself to result in neoplastic transformation. Further work will be required to map the breakpoints in constitutional and tumor-related t(11;22) more precisely. NCAM (38) , THY] (38), and T3D (39) at 11q23, and D22S9 (40) at 22q11 are other recently mapped genes that may prove useful as probes for further translocation breakpoint mapping. Ultimately, examination of sequences at or near the breakpoint junctions will be required, both to uncover mechanisms by which these recurrent translocations occur and to define which specific genes, if any, are altered by the translocation.
